![M. Boyd](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
M. Boyd
Keine laufenden Positionen mehr
Vermögen: 76 295 $ am 31.05.2026
Profil
M.
Cantey Boyd is an Independent Director at Kiniksa Pharmaceuticals International Plc since 2024.
Former positions include Director at Aquinox Pharmaceuticals, Inc., Director and Independent Director at Neoleukin Therapeutics, Inc., and Principal at Baker Bros.
Advisors LP.
Education includes undergraduate studies at Brown University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0 % | 06.04.2026 | 1.577 ( 0 % ) | 76 295 $ | 31.05.2026 |
Aktive Positionen von M. Boyd
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von M. Boyd
| Unternehmen | Position | Ende |
|---|---|---|
| NEUROGENE INC. | Direktor/Vorstandsmitglied | - |
Neoleukin Therapeutics, Inc. /old/
 Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Develops medicines that transform lives | Direktor/Vorstandsmitglied | - |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Direktor/Vorstandsmitglied | - |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Analyst-Equity | - |
Ausbildung von M. Boyd
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
4
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Finance |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Health Technology |
Neoleukin Therapeutics, Inc. /old/
Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Develops medicines that transform lives | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
